The National Institutes of Health anticipates spending more than $150 million over the next 5 years to renew its Pharmacogenetics Research Network, a nationwide collaboration of scientists working to help physicians tailor drug prescriptions to an individual’s genetic makeup.
Since 2000, the network has provided $140 million to scientists studying genes and medications relevant to a wide range of diseases, including asthma, depression, cancer, and heart disease (http://www.nigms.nih.gov/Initiatives/PGRN/Background/FiveYear.htm).
Hampton T. Pharmacogenetics Research. JAMA. 2005;294(20):2564. doi:10.1001/jama.294.20.2564-b